The US Food and Drug Administration conducted a PAI inspection at a subsidiary of Aurobindo Pharma, a company with operations in India and offices in Kerala.
2 reports, 2 independent
Updated Jul 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The US Food and Drug Administration conducted a PAI inspection at a subsidiary of Aurobindo Pharma, a company with operations in India and offices in Kerala.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- An inspection regarding API manufacturing standards was conducted at a facility in Srikakulam district, involving Aurobindo Pharma and Auroactive Pharma.Sub-event
US FDA inspected Aurobindo subsidiary while financial company based in India/Kerala.1 source